Aberrant Expression of Bacterial Pattern Recognition Receptor NOD2 of Basophils and Microbicidal Peptides in Atopic Dermatitis

Chun-Kwok Wong 1,2,*, Ida Miu-Ting Chu 1, Kam-Lun Hon 2,3, Miranda Sin-Man Tsang 2 and Christopher Wai-Kei Lam 4

1 Department of Chemical Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China; idachu1219@gmail.com
2 Institute of Chinese Medicine and State Key Laboratory of Phytochemistry and Plant Resources in West China, The Chinese University of Hong Kong, Hong Kong, China; ehon@cuhk.edu.hk (K.-L.H.); tsangsinman0128@gmail.com (M.S.-M.T.)
3 Department of Pediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China
4 State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China; wklam@must.edu.mo

* Correspondence: ck-wong@cuhk.edu.hk; Tel.: +852-2632-2964; Fax: +852-2636-5090

Abstract: Atopic dermatitis (AD) is a chronically relapsing inflammatory skin disease, associated with basophil infiltration into skin lesions and Staphylococcus aureus (S. aureus)-induced inflammation. Pattern recognition receptors (PRRs), including microbicidal peptide human neutrophil α-defensins (HNP) and dermcidin, can exert immunomodulating activity in innate immunity and skin inflammation. We investigated the plasma concentration of HNP and dermcidin, the expression of bacterial toll-like receptor (TLR) and nucleotide-binding oligomerization domain (NOD)-like receptors of basophils and plasma concentration and ex vivo induction of AD-related inflammatory cytokines and chemokines using ELISA and flow cytometry, in AD patients and control subjects. Plasma concentrations of HNP, dermcidin and AD-related Th2 chemokines CCL17, CCL22 and CCL27 were significantly elevated in AD patients compared with controls (all \( p < 0.05 \)). Plasma concentrations of CCL27 and CCL22 were found to correlate positively with SCORing atopic dermatitis (SCORAD), objective SCORAD, % area affected, lichenification and disease intensity, and CCL27 also correlated positively with pruritus in AD patients (all \( p < 0.05 \)). Protein expressions of NOD2 but not TLR2 of basophils were significantly down-regulated in AD patients compared with controls (\( p = 0.001 \)). Correspondingly, there were lower ex vivo % inductions of allergic inflammatory tumor necrosis factor-α, IL-6 and CXCL8 from peripheral blood mononuclear cells upon NOD2 ligand S. aureus derived muramyl dipeptide stimulation in AD patients comparing with controls. The aberrant activation of bacterial PRRs of basophils and anti-bacterial innate immune response should be related with the allergic inflammation of AD.

Keywords: antimicrobial peptides; atopic dermatitis; basophils; chemokines; pattern recognition receptors

1. Introduction

Atopic dermatitis (AD) is an important chronic relapsing inflammatory skin disease, especially in children, characterized by skin lesions with “lichenification”, pruritic excoriations and a susceptibility to cutaneous bacterial infections, that exhibits adverse impact on quality of life [1]. Basophils are...
rare circulating granulocytes (<1%) that contribute to the development of T helper (Th)2 immunity by elevated release of Th2 cytokines interleukin (IL)-4, IL-13, IL-17E/IL-25 and thymic stromal lymphopoiietin (TSLP) in allergic inflammation [2]. Basophils therefore serve as initiators and accessory cells for the Th2 cell polarization in response to protease allergens and recruit other effector cells such as eosinophils or neutrophils [3,4]. This type of chronic allergic inflammation requires basophils as initiators, through the interaction of antigens, IgE and FcRI [3,4]. Basophils are rarely found in normal tissues. However, they have been detected in skin lesions of AD and urticaria but not in psoriasis vulgaris, mastocytosis or tumoral lesions [5]. Infiltrated basophils are essential for IgE-mediated chronic AD and for protection against secondary infections such as *N. brasiliensis* [6]. Basophils also produce leukotriene C4 and histamine which can cause the symptoms of acute and chronic allergic inflammation [4–6]. Patients with AD have a unique predisposition to colonization or infection by the Gram positive bacterial *Staphylococcus aureus* (*S. aureus*) [1,7]. *S. aureus* can exacerbate or contribute to persistent skin inflammation in AD by secreting toxins with superantigenic properties, resulting in marked activation of T cells and other immune cells [8]. Toll-like receptors (TLR), a group of innate immunity-related pattern recognition receptors (PRR) that mediated the activation of eosinophils and dermal fibroblasts cells in allergic inflammation, have been extensively studied [9–11]. Cell surface TLR2 on keratinocytes recognizing bacterial cell wall component peptidoglycan (PGN) of *S. aureus* contributes to the innate immune response via intracellular signaling transduction [12,13]. Cytosolic PRR nucleotide binding oligomerization domain (NOD) like receptors (NLR) sense the conserved bacterial structural components [14,15]. NOD2-dependent recognition of *S. aureus* derived muramyl dipeptide (MDP) can trigger the innate immunity-mediated inflammation [11,16].

Principal human neutrophil defensins (α-defensins)/human neutrophil peptide (HNP)1-3 belong to the family of cationic trisulfide-containing microbicidal peptides. HNP exerts chemotactic, immunomodulating and cytotoxic activity and participates in innate immunity and inflammation [17]. Expression of human β-defensin (HBD2) was found to be reduced in AD lesions as compared with normal controls or psoriasis [18]. Up-regulation of HNP1-3 in T cells from patients with Stevens-Johnson syndrome/toxic epidermal necrolysis was demonstrated to relate with the etiopathology of these life-threatening diseases induced by medications [19]. Another antimicrobial peptide dermcidin is an anionic peptide and expressed in exocrine sweat glands and transported via sweat to the epidermal surface, with potent antimicrobial activity against *S. aureus*, *Escherichia coli* and candida [20–22]. Unlike human cathelicidins and β-defensins which are inducible peptides in response to injury and inflammation, dermcidin is involved in the constitutive innate defence of human skin and not inducible by skin injury or inflammation [21].

Under inflammatory conditions in AD skin, decreased expression of antimicrobial peptide genes and dermcidin in sweat of AD patients with local up-regulation of Th2 cytokines and the lack of elevated amounts of TNF-α and interferon (IFN)-γ have been reported [20,23,24]. However, the circulating levels of HNP1-3 and dermcidin in AD patients have not yet been well elucidated. Our recent *in vitro* and animal study demonstrated that NOD2/TLR2-mediated exacerbation of AD can be through the activation of basophils interacting with dermal fibroblasts and therefore sheds light on a novel mechanistic pathway by which *S. aureus* contributes to the pathophysiology of AD [11]. These result prompted us to further evaluate the expression of TLR2 and NOD2 of circulating basophils in AD patients. To investigate the bacterial infection-mediated innate immunity in allergic inflammation, the expression and cytokine inducing function of TLR2 and NOD2 of basophils, circulating antimicrobial peptide HNP and dermcidin and the AD-related chemokines CCL17, CCL22 and CCL27 were evaluated in the present cross-sectional clinical study.
2. Results and Discussion

2.1. AD Patients and Control Subjects

The clinical characteristics of the study population are summarized in Table 1. Twenty-seven AD patients and 15 control subjects were enrolled in this study, sharing with similar age range. The severity and symptoms of AD were assessed and presented using different clinical parameters such as SCORing atopic dermatitis (SCORAD) index, objective SCORAD, pruritus, sleep loss, skin hydration (SH), transepidermal water loss (TWEL), % skin area affected, lichenification and Children’s dermatology life quality index (CDLQI) (Table 1). All AD patients were found to have specific IgE against allergen house dust mites *Dermatophagoides pteronyssinus* (*D. pteronyssinus*) and most of them also have specific IgE against at least one of the following allergens including mixed cockroaches, cat dander, dog dander, mixed molds and *Staphylococcal* enterotoxin A, B and C. None of the control subjects presented with specific IgE against the above allergens. Functional basophil activation test (BAT) results showed that none of the control subjects exhibited positive BAT, but positive BAT upon the challenge by house dust mite Der p1, cockroach Bla g 2 and cat dander Fel d 1 protein was found in 96%, 78% and 70%, respectively, of total AD patients. Among all 27 recruited AD patients, 24 (88.9%) and 27 (100%) received topical corticosteroid and emollient treatment, respectively. Results in Table 1 therefore mainly confirm the disease severity and symptoms, as well as the IgE-mediated allergen sensitization in AD patients. Using cellular functional assay of IgE, result of basophil activation allergenicity test was found to be in concordance with the results of serum assay of specific IgE.

Table 1. Demographic, clinical and laboratory data of the atopic dermatitis (AD) patients.

| Parameters | AD Patients (n = 27) | Control Subjects (n = 15) |
|-----------|----------------------|--------------------------|
| Sex (male/female) | 15/12 | 5/10 |
| Age at evaluation, year (mean ± SD, range) | 14.3 ± 2.4 (9–18) | 21.2 ± 6.1 (10–29) |
| SCORAD index | 48.0 (40.5–61.7) | N.A. |
| Objective SCORAD index | 38.2 (29.9–47.0) | N.A. |
| Intensity (Erythema, Edema/Papulation, Oozing/Crusting, Excoration, Lichenification Dryness) | 8.0 (6.5–10.0) | N.A. |
| Pruritus | 7.0 (4.5–8.0) | N.A. |
| Sleep loss | 5.5 (0.0–7.5) | N.A. |
| SH | 24.6 (15.4–34.7) | N.A. |
| TWEL | 8.5 (7.8–10.8) | N.A. |
| Area affected (%) | 44 (35.8–64.0) | N.A. |
| Lichenification | 1.0 (1.0–2.0) | N.A. |
| CDLQI | 10.0 (4.5–15.5) | N.A. |
| Presence of at least one positive allergen-specific IgE, n (%) | | |
| *D. pteronyssinus*, n (%) | 27 (100) | 0 (0) |
| Cockroaches, n (%) | 16 (59) | 0 (0) |
| Cat dander, n (%) | 13 (48) | 0 (0) |
| Dog dander, n (%) | 21 (78) | 0 (0) |
| Mixed molds, n (%) | 18 (67) | 0 (0) |
| *Staphylococcal* enterotoxin A, n (%) | 16 (59) | 0 (0) |
| *Staphylococcal* enterotoxin B, n (%) | 14 (52) | 0 (0) |
| *Staphylococcal* enterotoxin C, n (%) | 12 (44) | 0 (0) |
| Positive basophil activation test | | |
| House dust mite, *D. pteronyssinus*, n (%) | 26 (96) | 0 (0) |
| Cockroaches, Bla g 2 protein, n (%) | 21 (78) | 0 (0) |
| Cat dander, Fel d 1 protein, n (%) | 19 (70) | 0 (0) |
| Positive *S. aureus* growth (wound swabs), n (%) | 18 (70) | N.A. |
| Treatment | | |
| Topical corticosteroid | 24 (89) | N.A. |
| Emollient | 27 (100) | N.A. |

Values were given as median (IQR) or mean ± SD. SCORAD: SCORing atopic dermatitis, N.A.: not applicable, SH: skin hydration, TWEL: transepidermal water loss, CDLQI: Children’s Dermatology Life Quality Index.
2.2. Plasma Concentrations of AD-Related Chemokines and Bacterial Infection-Related Dermcidin and HNP

Plasma concentrations of AD-related chemokine CCL27, CCL22 and CCL17 and antimicrobial peptides HNP and dermcidin were significantly higher in AD patients than in control subjects (median (IQR) of CCL27, CCL22, CCL17, HNP and dermcidin for AD patients vs. controls: 992.9 (754.1–1525) vs. 679 (519.6–751.5) pg/mL, \( p = 0.0005 \); 1435 (855–2105) vs. 598.2 (525.7–712.4) pg/mL, \( p < 0.0001 \); 83.6 (40.4–244.1) vs. 10.9 (8.7–25.8) pg/mL, \( p < 0.0001 \); 2245 (1863–3150) vs. 1783 (1412–2192) pg/mL, \( p = 0.0294 \) and 7.2 (5.9–8.1) vs. 5.4 (5.0–6.6) ng/mL, \( p = 0.003 \), respectively, all \( p < 0.05 \), Figure 1). As shown in Figure 2, plasma concentrations of CCL27 were found to be correlated significantly with SCORAD, objective SCORAD, % area affected, lichenification, disease intensity and pruritus (all \( p < 0.05 \)), exhibiting strong correlation with % area affected and disease intensity (both \( r > 0.8 \)). Plasma concentrations of CCL22 were also correlated significantly with SCORAD, objective SCORAD, % area affected, lichenification and disease intensity (all \( p < 0.05 \)) with weaker Spearman’s rank correlation coefficient comparing with that of CCL27.

![Figure 1](image_url)

**Figure 1.** Plasma concentrations of CCL27, CCL22, CCL17, HNP and dermcidin in AD patients and normal controls. Box and whiskers plots showing comparisons of plasma concentrations of (a) CCL27; (b) CCL22; (c) CCL17; (d) HNP and (e) dermcidin between AD patients and control subjects were determined by Mann-Whitney rank sum test.
Figure 1. Plasma concentrations of CCL27, CCL22, CCL17, HNP and derm cidin in AD patients and normal controls. Box and whiskers plots showing comparisons of plasma concentrations of (a) CCL27, (b) CCL22; (c) CCL17; (d) HNP and (e) dermcidin between AD patients and control subjects were determined by Mann-Whitney rank sum test.

Figure 2. Cont.
Figure 2. Correlations between plasma concentrations of CCL27 and CCL22 with SCORAD, objective SCORAD, % area affected, lichenification, disease intensity and pruritus in AD patients. Correlation and significant were determined by non-parametric Spearman’s correlation test.

CCL27/cutaneous T-cell-attracting chemokine (CTACK) is a T-cell attracting chemokine for the regulation of infiltration and accumulation of memory T lymphocytes to the skin, therefore, it plays a role in T cell-mediated skin inflammation in AD [25–27]. CCL27 produced by keratinocytes, gonads, thymus and placenta can bind to its receptor CCR10 on skin-homing T cells [27]. Previous studies showed the elevated CCL27 levels were significantly correlated with AD severity [25,26]. However, our correlation coefficient between CCL27 with SCORAD and objective SCORD was about 0.78 which is higher than the previously reported 0.68 [25]. CCL22/macrophage-derived
chemokine (MDC) is secreted by dendritic cells and macrophages to elicit its effects on its target cells by interacting with cell surface chemokine receptors CCR4 [28]. CCL17 (thymus and activation regulated chemokine/TARC) is a basic protein which also acts on the chemokine receptor CCR4 on peripheral blood mononuclear cells (PBMC) and human T lymphocytes [29]. CCL17 could induce selective migration of lymphocytes, especially Th2 cells [29–31]. Therefore, CCR4-CCL22/CCL17 interaction is crucial in regulating the chemotaxis of Th2 lymphocytes into local inflammatory sites of allergic inflammation [30,32]. Elevated serum levels of CCL17 and CCL22 have previously been shown to be significantly correlated with the AD severity [33–35]. Together, our present results further confirmed the elevated crucial chemokines CCL17, CCL22 and CCL27 in AD, leading to the accumulation of Th2 cells and eosinophils/basophils and overexpression of Th2 cytokine IL-4, IL-10 and IL-13, and corresponding suppression of anti-microbial peptide expression at local skin lesions [36]. Therefore, the elevated production of chemokines eventually leads to enhanced *S. aureus*-mediated persistent skin inflammation which correlates with and exacerbates the AD disease severity. CCL27 and CCL22 can therefore serve as surrogate biomarkers for monitoring disease severity in AD.

Further analysis of the neutrophil-derived HNP and sweat glands-derived dermcidin showed that the plasma concentrations of HNP and dermcidin were significantly elevated in AD patients (all \( p < 0.05 \)). Results therefore indicated that up-regulated circulating anti-bacterial innate immunity which is different from the down-regulated/defective anti-bacterial innate immunity at local skin lesions [23,24,37]. The impaired anti-*S. aureus*-mediated innate immunity in skin may increase the access of bacteria into the circulation, thereby activating the systemic, especially neutrophil-mediated innate immunity, resulting in elevated circulating level of HNP and dermcidin. Deriving from the present clinical setting, results therefore indicated the dermcidin and HNP may play crucial roles for the regulation of circulating innate immunity in response to infection and injury in AD [17,19,38]. Since HDN and dermcidin can exert immunomodulating activity in innate immunity, their circulating elevation may participate in allergic inflammation in AD [17,19]. Other innate immunity-related molecules including LL37, neopterin and psoriasin however did not exhibit any significant difference between AD patients and controls subjects (all \( p > 0.05 \), data not shown).

### 2.3. Expression of TLR2 and NOD2 in CD203+ Granulocytes

TLR2 and NOD2 can provoke cutaneous immune response against *S. aureus* by activating NF-κB-mediated production of AD-related chemokines and anti-microbial peptides [39], and basophils are the principal effector cells in allergic inflammation of AD [11]. In order to assess bacterial-infection related innate immunity in AD, we therefore investigated the expression of *S. aureus*-related PRR TLR2 and NOD2 in CD203+ basophils obtained from AD patients and controls. As shown in Figure 3a,b, the gated CD203+ granulocytes could denote the basophil population in total granulocytes and the expression of NOD2 and TLR2 of basophils. In Figure 3c, further analysis found that intracytosolic NOD2 but not cell surface TLR2 expression was significantly lower in AD patients than in control subjects (median (IQR) of NOD2 and TLR2 (MFI) for AD patients vs. controls: 2.04 (1.48–2.68) vs. 4.92 (3.47–7.30), \( p = 0.0011 \); 0.91 (0.53–1.39) vs. 0.62 (0.24–1.03), \( p = 0.068 \), respectively). Correspondingly, the % increase of the *ex vivo* induction of inflammatory cytokines TNF-α, IL-6 and CXCL8 upon NOD2 ligand MDP stimulation was found to be higher in PBMC culture from control subjects than that of AD patients (median (IQR) of % increase in TNF-α, IL-6 and CXCL8 for AD patients vs. controls: 20 (0–375) vs. 55 (15–290) %; 130 (35–600) vs. 285 (165–660) %; 100 (55–220) vs. 160 (80–225) %, respectively, Figure 4).

The above results therefore demonstrated the down-regulation of NOD2-mediated innate immunity of allergic inflammatory basophils in AD patients. Our recent findings have also demonstrated the down-regulation of NOD2 expression in eosinophils in patients with allergic asthma [40]. Together with the present results, bacterial PRR of granulocytes eosinophils and basophils seems to be impaired in allergy, linking the aberrant innate immunity with allergic inflammation in allergic diseases.
Figure 3. Expression of TLR2 and NOD2 in CD203-positive granulocytes. (a) Representative histogram is shown for the CD203+ cells gated from total granulocytes; (b) Representative histograms of the cell surface expression of TLR2 and intracellular expression of NOD2 of CD203c+ granulocytes are shown. (c) Box and whiskers plots showing the comparison of cell surface TLR2 and intracellular NOD2 expression (MFI) in CD203+granulocytes between AD patients and control subjects were determined by Mann-Whitney rank sum test. AD: patients with atopic dermatitis; Control: normal control subjects.
was assessed using the SCORAD index system (range 0–103) \[42,43\]. Skin biophysiologic parameters
measured by standardized procedure following acclimatization to eliminate the seasonal effects on the measurements \[43\]. Fifteen corresponding non-allergic normal control subjects with similar age range were recruited. Control subjects did not have any history of allergic or inflammatory disease and did not require any drug treatment at the time of study. All recruited subjects were free from intercurrent illness including respiratory tract infection and allergic asthma, and they had not used any systemic corticosteroids for 4 weeks prior to enrollment in the study. The atopic status of these patients and control subjects was ascertained by positive serum-specific IgE assays to house dust mite D. pteronyssinus, cat dander, dog dander, mixed cockroaches, mixed molds and Staphylococcus enterotoxin A, B and C by fluorescence enzyme immunoassay (AutoCAP analyzer, Pharmacia Diagnostics AB, Uppsala, Sweden) \[44–46\] and basophil activation test \[40\]. S. aureus growth from wound swabs was obtained from AD patients to document current S. aureus colonization. Sixteen milliliters (mL) of EDTA-anticoagulated and 3 mL clotted venous peripheral blood were collected from each patient and control subject for analysis. Plasma and serum samples were preserved at −80 °C for subsequent assays. The above protocol was approved by the Clinical Research Ethics Committee of the Chinese University of Hong Kong-New Territories East Cluster Hospitals, and informed written consent was obtained from all subjects or their parents in accordance with the 1964 Declaration of Helsinki and its later amendments.
3.2. Flow Cytometric Analysis for TLR2 and NOD2 Expression in CD203+ Basophils from AD Patients and Controls

Peripheral blood granulocytes from AD patients and control subjects were purified using Percoll gradient centrifugation (GE Healthcare Life Sciences, Pittsburgh, PA, USA). The expression of TLR2 and NOD2 of CD203c+ granulocytes of AD patients and control subjects was determined by flow cytometry (Navios Flow Cytometer, Beckman Coulter Inc., Miami, FL, USA) as previously described [40,47]. Murine serum-blocked granulocytes were fixed and permeabilized using Fix/Perm solution (BD Biosciences Corp., San Jose, CA, USA) for the cell surface and intracellular staining of TLR2 and NOD2, respectively. Unconjugated mouse anti-TLR2 (Imgenex Corp., San Diego, CA, USA), anti-NOD2 antibody (Bio-legend Corp, San Diego, CA, USA), corresponding mouse IgG1, k isotypic control antibody (BD Pharmingen Corp., San Diego, CA, USA), together with a fluorescein iso-thiocyanate (FITC)-conjugated goat anti-mouse IgG (H + L) secondary antibodies (Zymed Laboratories, Inc., South San Francisco, CA, USA), were used for staining. The expression of TLR2 and NOD2 of final granulocyte suspension with 10,000 events was assessed using flow cytometry with gating by CD203, a specific activation marker on basophils (Navios Flow Cytometer). Results were expressed as mean fluorescence intensity (MFI).

3.3. Quantitative Analysis of Plasma Concentrations of Chemokines, Dermcidin and HNP

Plasma concentrations of chemokines were measured by Bio-plex human cytokine multiplex assay with the Bio-plex 200 System (Bio-Rad Laboratories, Inc., Hercules, CA, USA), while plasma concentrations of dermcidin and HNP were measured by enzyme-linked immunosorbent assay (ELISA) reagents from MyBiosource, San Diego, CA, USA, and Hycult Biotech Inc., Plymouth Meeting, PA, USA, respectively.

3.4. Assay of Serum IgE

Serum specific IgE against house dust mite (Der p1), cat and dog dander, mixed cockroaches, mixed molds, Staphylococcal enterotoxin A, B and C were measured to ascertain the atopic status of all participants using fluorescence enzyme immunoassay (ImmunoCAP immunoassay analyzer, Phadia, Uppsala, Sweden) [46,48].

3.5. Basophil Activation Test (BAT)

To further assess the IgE-mediated allergic inflammation, we evaluated the functional basophil-bound-specific IgE using specific allergen-mediated BAT (Allergenicity Assay Kit, Beckman Coulter). This is a cellular functional analysis based on flow cytometric analysis of the IgE-mediated up-regulation of the cell surface expression of activation marker CD203c associated with cellular degranulation on basophils upon the ex vivo allergen challenge such as house dust mite, cockroaches, and cat dander [40,49]. Using an accurate basophil gating tool (CRTH2+ CD203c+ CD3–), BAT was performed on whole blood specimen by flow cytometer (Navios Flow Cytometer, Beckman Coulter).

3.6. Ex Vivo Induction of Inflammatory Cytokines from PBMC

After a maximum storage period of 1 h of freshly collected EDTA blood at room temperature, PBMC were purified using Ficoll-Paque gradient centrifugation (GE healthcare Life Sciences, NJ, USA). PBMC (1 × 10^6/mL) was then incubated with or without NOD2 ligand muramyl dipeptide (MDP, 1 µg/mL) (Invivogen Corp, San Diego, CA, USA) for 24 h at 37 °C in a 5% CO₂ atmosphere. After incubation, the cell free supernatant of ex vivo culture was harvested and stored at −70 °C for subsequent assay of inflammatory cytokines using human inflammatory cytokine cytometric bead array (CBA) kit with the FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA) [50]. The % increase of the cytokine induction by PGN and MDP was calculated by (concentration of
cytokines stimulated by ligand – basal concentration of cytokines without any stimulation)/basal concentration of cytokine without any stimulation × 100%.

3.7. Statistical Analysis

The non-parametric Mann-Whitney rank sum test was used to compare the differences between different groups, and the Spearman’s rank correlation test was used to assess the correlations among different measurable parameters. All analyses were performed using Statistical Package for the Social Sciences (SPSS) statistical software for Windows, Version 20 (SPSS Inc., Chicago, IL, USA). A probability \( p < 0.05 \) was considered as statistically significant.

4. Conclusions

Elevated circulating Th2 chemokines are related to the infiltration of Th2 cells and the accumulation of eosinophils/basophils with the inhibition of the expression of anti-microbial peptides at skin lesions. These lead to worsening symptoms and increased disease severity scores in AD. Therefore, the impaired anti-bacterial innate immunity has been shown to account for the enhanced skin bacterial infections in AD [23,24,37]. In the present study, the defective PRR have been identified for allergic inflammatory basophils. Together with lower cytokine response upon NOD2 ligand stimulation and lower concentration of anti-microbial peptides HNP and dermcidin at local skin lesions, the local innate immune mechanisms against \( S. \) aureus could be down-regulated in AD. This may subsequently lead to enhanced \( S. \) aureus proliferation at skin lesions, and bacteria or its pattern associated molecular pattern molecules may penetrate into the blood circulation to stimulate the neutrophils and other immune effector cells-mediated innate immunity in circulation to result in increased plasma levels of HNP and dermcidin. The present study may provide further evidence for the elucidation of these defects of innate immunity and allow the development of novel therapeutic intervention to repair these deficiencies and reduce the allergic inflammation in AD patients.

Acknowledgments: This work was supported by the Research Grant Committee General Research Fund, Hong Kong (Project Ref. No. CUHK476813, Principal investigator: CKW) and Direct Grant from The Chinese University of Hong Kong (project code: 2011.1.011).

Author Contributions: C.K.W. conceived and designed the study. K.-L.H. recruited the patients and control subjects. I.M.-T.C. and M.S.-M.T. performed the experiments. C.K.W. and C.W.K.L. wrote the manuscript.

Conflicts of Interest: The authors declare that there is no conflict of interest regarding the publication of this paper.

References

1. Boguniewicz, M.; Leung, D.Y. Atopic dermatitis: A disease of altered skin barrier and immune dysregulation. *Immunol. Rev.* 2011, 242, 233–246. [CrossRef] [PubMed]
2. Sokol, C.L.; Barton, G.M.; Farr, A.G.; Medzhitov, R. A mechanism for the initiation of allergen-induced T helper type 2 responses. *Nat. Immunol.* 2008, 9, 310–318. [CrossRef] [PubMed]
3. Mukai, K.; Matsuoka, K.; Taya, C.; Suzuki, H.; Yokozeki, H.; Nishioka, K.; Hirokawa, K.; Etori, M.; Yamashita, M.; Kubota, T.; *et al.* Basophils play a critical role in the development of IgE-mediated chronic allergic inflammation independently of T cells and mast cells. *Immunity* 2005, 23, 191–202. [CrossRef] [PubMed]
4. Obata, K.; Mukai, K.; Tsujimura, Y.; Ishiwata, K.; Kawano, Y.; Minegishi, Y.; Watanabe, N.; Karasuyama, H. Basophils are essential initiators of a novel type of chronic allergic inflammation. *Blood* 2007, 110, 913–920. [CrossRef] [PubMed]
5. Ito, Y.; Satoh, T.; Takayama, K.; Miyagishi, C.; Walls, A.F.; Yokozeki, H. Basophil recruitment and activation in inflammatory skin diseases. *Allergy* 2011, 66, 1107–1113. [CrossRef] [PubMed]
6. Ohnmacht, C.; Schwartz, C.; Panzer, M.; Schiedewitz, I.; Naumann, R.; Voehringer, D. Basophils orchestrate chronic allergic dermatitis and protective immunity against helminths. *Immunity* 2010, 33, 364–374. [CrossRef] [PubMed]
7. Hong, S.W.; Kim, M.R.; Lee, E.Y.; Kim, J.H.; Kim, Y.S.; Jeon, S.G.; Yang, J.M.; Lee, B.J.; Pyun, B.Y.; Gho, Y.S.; et al. Extracellular vesicles derived from Staphylococcus aureus induce atopic dermatitis-like skin inflammation. *Allergy* 2011, 66, 351–359. [CrossRef] [PubMed]

8. Schlievert, P.M.; Strandberg, K.; Lin, Y.C.; Peterson, M.L.; Leung, D.Y. Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive Staphylococcus aureus, and its relevance to atopic dermatitis. *J. Allergy Clin. Immunol.* 2010, 125, 39–49. [CrossRef] [PubMed]

9. Wong, C.K.; Cheung, P.F.; Ip, W.K.; Lam, C.W. Intracellular signaling mechanisms regulating toll-like receptor-mediated activation of eosinophils. *Am. J. Respir. Cell Mol. Biol.* 2007, 37, 85–96. [CrossRef] [PubMed]

10. Cheung, P.F.; Wong, C.K.; Ip, W.K.; Lam, C.W. FAK-mediated activation of ERK for eosinophil migration: A novel mechanism for infection-induced allergic inflammation. *Int. Immunol.* 2008, 20, 353–363. [CrossRef] [PubMed]

11. Jiao, D.; Wong, C.K.; Qiu, H.N.; Dong, J.; Cai, Z.; Chu, M.; Hon, K.L.; Tsang, M.S.; Lam, C.W. NOD2 and TLR2 ligands trigger the activation of basophils and eosinophils by interacting with dermal fibroblasts in atopic dermatitis-like skin inflammation. *Cell. Mol. Immunol.* 2015. [CrossRef] [PubMed]

12. Mempel, M.; Voelcker, V.; Kollisch, G.; Plank, C.; Rad, R.; Gerhard, M.; Schnopp, C.; Fraunberger, P.; Walli, A.K.; Ring, J.; et al. Toll-like receptor expression in human keratinocytes: Nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. *J. Investig. Dermatol.* 2003, 121, 1389–1396. [CrossRef] [PubMed]

13. Niebuhr, M.; Baumert, K.; Werfel, T. TLR-2-mediated cytokine and chemokine secretion in human keratinocytes. *Exp. Dermatol.* 2010, 19, 873–877. [CrossRef] [PubMed]

14. Schroeder, K.; Tschopp, J. The inflammasomes. *Cell* 2010, 140, 821–832. [CrossRef] [PubMed]

15. Davis, B.K.; Wen, H.; Ting, J.P. The inflammasome NLRs in immunity, inflammation, and associated diseases. *Annu. Rev. Immunol.* 2011, 29, 707–735. [CrossRef] [PubMed]

16. Hruz, P.; Zinkernagel, A.S.; Jenikova, G.; Botwin, G.J.; Hugot, J.P.; Karin, M.; Nizet, V.; Eckmann, L. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. *N. Engl. J. Med.* 2002, 347, 1151–1160. [CrossRef] [PubMed]

17. Doss, M.; White, M.R.; Tecle, T.; Hartshorn, K.L. Human defensins and LL-37 in mucosal immunity. *J. Leukoc. Biol.* 2010, 87, 79–92. [CrossRef] [PubMed]

18. Ong, P.Y.; Ohtake, T.; Brandt, C.; Strickland, I.; Boguniewicz, M.; Ganz, T.; Gallo, R.L.; Leung, D.Y. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. *N. Engl. J. Med.* 2002, 347, 1151–1160. [CrossRef] [PubMed]

19. Morel, E.; Alvarez, L.; Cabañas, R.; Fiandor, A.; Díaz, R.; Escamochero, S.; Prior, N.; Blanca, M.; Bellón, T. Expression of α-defensin 1–3 in T cells from severe cutaneous drug-induced hypersensitivity reactions. *Allergy* 2011, 66, 360–367. [CrossRef] [PubMed]

20. Hata, T.R.; Gallo, R.L. Antimicrobial peptides, skin infections, and atopic dermatitis. *Semin. Cutan. Med. Surg.* 2008, 27, 144–150. [CrossRef] [PubMed]

21. Rieg, S.; Garbe, C.; Sauer, B.; Kalbacher, H.; Schittek, B. Dermcidin is constitutively produced by eccrine sweat glands and is not induced in epidermal cells under inflammatory skin conditions. *Br. J. Dermatol.* 2004, 151, 534–539. [CrossRef] [PubMed]

22. Lai, Y.P.; Peng, Y.F.; Zuo, Y.; Li, J.; Huang, J.; Wang, L.F.; Wu, Z.R. Functional and structural characterization of recombinant dermcidin-1L, a human antimicrobial peptide. *Biochem. Biophys. Res. Commun.* 2005, 328, 243–250. [CrossRef] [PubMed]

23. Nomura, I.; Goleva, E.; Howell, M.D.; Hamid, Q.A.; Ong, P.Y.; Hall, C.F.; Darst, M.A.; Gao, B.; Boguniewicz, M.; Travers, J.B.; et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. *J. Immunol.* 2003, 171, 3262–3269. [CrossRef] [PubMed]

24. Rieg, S.; Steffen, H.; Seeber, S.; Humeny, A.; Kalbacher, H.; Dietz, K.; Garbe, C.; Schittek, B. Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo. *J. Immunol.* 2005, 174, 8003–8010. [CrossRef] [PubMed]

25. Thijs, J.; Krastev, T.; Weidinger, S.; Buckens, C.F.; de Bruin-Weller, M.; Bruijnzeel-Koomen, C.; Flohr, C.; Hijnen, D. Biomarkers for atopic dermatitis: A systematic review and meta-analysis. *Curr. Opin. Allergy Clin. Immunol.* 2015, 15, 453–460. [CrossRef] [PubMed]
26. Machura, E.; Rusek-Zychma, M.; Jachimowicz, M.; Wrzask, M.; Mazur, B.; Kasperska-Załac, A. Serum TARC and CTACK concentrations in children with atopic dermatitis, allergic asthma, and urticaria. *Pediatr. Allergy Immunol.* **2012**, *23*, 278–284. [CrossRef] [PubMed]

27. Homey, B.; Alenius, H.; Müller, A.; Soto, H.; Bowman, E.P.; Yuan, W.; McEvoy, L.; Lauerma, A.I.; Assmann, T.; Bünnemann, E.; et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. *Nat. Med.* **2002**, *8*, 157–165. [CrossRef] [PubMed]

28. Vulcano, M.; Albanesi, C.; Stopparciaro, A.; Bagnati, R.; D’Amico, G.; Struyf, S.; Transidico, P.; Bonecchi, R.; del Prete, A.; Allavena, P.; et al. Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in *vitro* and in *vivo*. *Eur. J. Immunol.* **2001**, *31*, 812–822. [CrossRef]

29. Imai, T.; Baba, M.; Nishimura, M.; Kakizaki, M.; Takagi, S.; Yoshie, O. The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4. *J. Biol. Chem.* **1997**, *272*, 15036–15042. [CrossRef] [PubMed]

30. Imai, T.; Nagira, M.; Takagi, S.; Kazikizaki, M.; Nishimura, M.; Wang, J.; Gray, P.W.; Matsushima, K.; Yoshie, O. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage derived chemokine. *Int. Immunol.* **1999**, *11*, 81–88. [CrossRef] [PubMed]

31. Bonecchi, R.; Bianchi, G.; Bordignon, P.P.; D’Ambrosio, D.; Lang, R.; Borsatti, A.; Sozzani, S.; Allavena, P.; Gray, P.A.; Mantovani, A.; et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. *J. Exp. Med.* **1998**, *187*, 129–134. [CrossRef] [PubMed]

32. Imai, T.; Chantry, D.; Raport, C.J.; Wood, C.L.; Nishimura, M.; Godiska, R.; Yoshie, O.; Gray, P.W. Macrophage derived chemokine is a functional ligand for the CC chemokine receptor 4. *J. Biol. Chem.* **1998**, *273*, 1764–1768. [CrossRef] [PubMed]

33. Kakinuma, T.; Nakamura, K.; Wakugawa, M.; Mitsui, H.; Tada, Y.; Saeki, H.; Torii, H.; Asahina, A.; Onai, N.; Matsushima, K.; et al. Thymus and activation regulated chemokine in atopic dermatitis: Serum thymus and activation regulated chemokine is closely related with disease activity. *J. Allergy Clin. Immunol.* **2001**, *107*, 535–541. [CrossRef] [PubMed]

34. Kakinuma, T.; Nakamura, K.; Wakugawa, M.; Mitsui, H.; Tada, Y.; Saeki, H.; Torii, H.; Komine, M.; Asahina, A.; Tamaki, K. Serum macrophage-derived chemokine (MDC) levels is closely related with the disease activity of atopic dermatitis. *Clin. Exp. Immunol.* **2002**, *127*, 270–273. [CrossRef] [PubMed]

35. Hashimoto, S.; Nakamura, K.; Oyama, N.; Kaneko, F.; Tsunemi, Y.; Saeki, H.; Tamaki, K. Macrophage-derived chemokine (MDC)/CCL22 produced by monocyte derived dendritic cells reflects the disease activity in patients with atopic dermatitis. *J. Dermatol. Sci.* **2006**, *44*, 93–99. [CrossRef] [PubMed]

36. Homey, B.; Steinhoff, M.; Ruzicka, T.; Leung, D.Y. Cytokines and chemokines orchestrate atopic skin inflammation. *J. Allergy Clin. Immunol.* **2006**, *118*, 178–189. [CrossRef] [PubMed]

37. Shiohara, T.; Doi, T.; Hayakawa, J. Defective sweating responses in atopic dermatitis. *Curr. Probl. Dermatol.* **2011**, *41*, 68–79. [PubMed]

38. Wang, E.; Qiang, X.; Li, J.; Zhu, S.; Wang, P. The *in Vitro* Immune-Modulating Properties of a Sweat Gland-Derived Antimicrobial Peptide Dermcidin. *Shock* **2016**, *45*, 28–32. [CrossRef] [PubMed]

39. Ryu, S.; Song, P.I.; Seo, C.H.; Cheong, H.; Park, Y. Colonization and infection of the skin by *S. aureus*: Immune system evasion and the response to cationic antimicrobial peptides. *Int. J. Mol. Sci.* **2014**, *15*, 8753–8772. [CrossRef] [PubMed]

40. Wong, C.K.; Leung, T.F.; Chu, I.M.; Dong, J.; Lam, Y.Y.; Lam, C.W. Aberrant Expression of Regulatory Cytokine IL-35 and Pattern Recognition Receptor NOD2 in Patients with Allergic Asthma. *Inflammation* **2015**, *38*, 348–360. [CrossRef] [PubMed]

41. Hanifi, J.M.; Rajka, G. Diagnostic features of atopic dermatitis. *Acta Derm. Venereol.* **1980**, *2*, 44–47.

42. Severity scoring of atopic dermatitis: The SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. *Dermatology* **1993**, *186*, 23–31.

43. Hon, K.L.; Wong, K.Y.; Leung, T.F.; Chow, C.M.; Ng, P.C. Comparison of skin hydration evaluation sites and correlations among skin hydration, transepidermal water loss, SCORAD Index, Nottingham Eczema Severity Score, and quality of life in patients with atopic dermatitis. *Am. J. Clin. Dermatol.* **2008**, *9*, 45–50. [CrossRef] [PubMed]
44. Wehner, J.; Neuber, K. *Staphylococcus aureus* enterotoxins induce histamine and leukotriene release in patients with atopic eczema. *Br. J. Dermatol.* 2001, 145, 302-305. [CrossRef] [PubMed]

45. Wong, C.K.; Ho, C.Y.; Ko, F.W.; Chan, C.H.; Ho, A.S.; Hui, D.S.; Lam, C.W. Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-gamma, IL-4, IL-10 and IL-13) in patients with allergic asthma. *Clin. Exp. Immunol.* 2001, 125, 177–183. [CrossRef] [PubMed]

46. Leung, T.F.; Sy, H.Y.; Wong, G.W.; Ng, M.C.; Chan, I.H.; Li, C.Y.; Tang, N.L.; Waye, M.W.; Lam, C.W. Asthma and atopy are associated with chromosome 17q21 markers in Chinese children. *Allergy* 2009, 64, 621–628. [CrossRef] [PubMed]

47. Wong, C.K.; Hu, S.; Leung, K.M.; Dong, J.; He, L.; Chu, Y.J.; Chu, I.M.; Qiu, H.N.; Liu, K.Y.; Lam, C.W. NOD-like receptors mediated activation of eosinophils interacting with bronchial epithelial cells: A link between innate immunity and allergic asthma. *Cell. Mol. Immunol.* 2013, 10, 317–329. [CrossRef] [PubMed]

48. Leung, T.F.; Wong, C.K.; Chan, I.H.; Ip, W.K.; Lam, C.W.; Wong, G.W. Plasma concentration of thymus and activation-regulated chemokine is elevated in childhood asthma. *J. Allergy Clin. Immunol.* 2002, 110, 404–409. [CrossRef] [PubMed]

49. Chirumbolo, S. Basophil activation test in allergy: Time for an update? *Int. Arch. Allergy Immunol.* 2012, 158, 99–114. [CrossRef] [PubMed]

50. Wong, C.K.; Lit, L.C.; Tam, L.S.; Li, E.K.; Wong, P.T.; Lam, C.W. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: Implications for Th17-mediated inflammation in auto-immunity. *Clin. Immunol.* 2008, 127, 385–393. [CrossRef] [PubMed]

**Sample Availability:** Samples of the compound muramyl dipeptide are available from the authors.

© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).